Pharmaceutical Innovation and Production: Global Trends and Legal Challenges.

New tariffs imposed by the United States starting October 1 2025 include a 100% tariff on brand-name or patented medicines affecting the pharmaceutical sector, unless the drugmaker is in the process of building a manufacturing facility “breaking ground” or “under construction” within the U.S. This has led to concerns about pharmaceutical stocks, supply shortages, potential higher costs for patients, and questions on possible expansion of tariffs to generic and biosimilar pharmaceutical products, which are so far excluded.

The aim of the tariffs is to encourage the largest global pharmaceutical companies to reshore manufacturing. US imports of pharmaceutical products increased dramatically in recent years, reaching over $212 billion in 2024. The pharmaceutical industry builds its corporate governance and products carefully into segmented markets and jurisdictions with different legal and healthcare systems and pricing and reimbursement rules influencing where the most critical and advanced therapies are sold, and at what price.  Market access and advanced manufacturing of pharmaceuticals were important considerations in the trade deal between the EU and US in July 2025.

Depending on the country’s procurement model, decisions determining patient access to medicinal products can rely on rationed national healthcare budgets and policy. In Europe that means at least 27 different medicines pricing and reimbursement systems. EU pricing and reimbursement decisions are the responsibility of each member state rather than centralized at the EU level. Unavailability and delayed market access to innovative medicines is evident in Europe’s smaller markets, particularly Croatia, Cyprus, Estonia, Latvia, Lithuania, Malta, Slovenia, Montenegro and North Macedonia. Patients in some European countries must often wait over 800 days longer for a new medicine. Regulatory and pricing changes in major markets, particularly the US, EU, and China, influence innovation incentives and supply chain strategies.

The future of global pharmaceutical production and procurement is poised for significant change for several reasons: the use of technology and AI, personalized medicine, new therapeutic areas beyond traditional oncology and immunology, digital health, and regulatory innovation. In 2025, oncology, immunology, neurology, and metabolic diseases such as diabetes and obesity, are the highest-cost therapeutic areas driving pharmaceutical companies’ revenue, R&D investment, and health science innovation.

The United States is the largest pharmaceutical purchaser in the world.  U.S. President Trump’s letter to pharmaceutical executives of 31 July 2025 mentioned sale of direct-to-consumer prescription medicines by the pharmaceutical manufacturers. The direct to consumer option for select medicinal products is intended to allow patients to buy medicines directly at internationally competitive prices—including Medicaid, Medicare, and private insurance patients– and reduce costs by eliminating middle layers in the supply chain.

The U.S. generally pays the highest prices for prescription medicines globally, both in total spending and per capita. Drug prices in the U.S. are nearly three times higher on average compared to 33 high-income countries. The Inflation Reduction Act drug price negotiation programaims to lower costs on the drugs representing the highest spend and lack of competition under Medicare Part D, however it only covers one-third of Medicare’s Part D drug costs. Medicare is currently negotiating prices on 25 drugs that treat conditions including cancer, diabetes and weight loss, asthma, psoriasis and psoriatic arthritis, multiple myeloma and more. The negotiated price for the first 10 drugs takes effect in 2026, and the next 15 selected drugs will have negotiated prices in 2027.

The United States’ pharmaceutical market is approximately $669 billion in 2025, making it the largest single country market globally. It is forecasted to grow at a compound annual growth rate (CAGR) of about 5.7% from 2025 to 2030, reaching nearly USD 884 billion by 2030. China has an estimated $284.9 billion market size, Japan around $100.4 billion, and significant markets in Germany, France, the UK, and India. The size of the EU pharmaceutical market as a whole in 2024 is estimated at $488 billion (around €448 billion), with projections to grow to approximately $688 billion by 2030, at a compound annual growth rate (CAGR) of about 5.9% from 2025 to 2030. Life sciences add nearly €1.5 trillion in value to the EU economy and support 29 million jobs across the EU.

The pharmaceutical industry is strategically expanding into high-growth emerging markets, such as China, India, Indonesia, Vietnam, South Africa, Brazil, Mexico, Argentina, Colombia, Uruguay, and Turkey, to tap future potential and diversify.  Understanding the impact this will have on supply chains, the U.S. is invested in reshoring pharmaceutical manufacturing and maximizing domestic production to redirect global supply chains in the interest of national security under Section 232 of the U.S. Trade Expansion Act. New York City has a $1 billion initiative aimed to create 40,000 jobs and establish the city as a global leader in the life sciences industry. Since January 2025, the pharmaceutical industry has pledged over $160 billion in total investment to the USA.

The global pharmaceutical markets tend to deviate from free market principles. There is some interest in transparency and patient choice to move in the direction of free market dynamics. In a free market, product prices are determined by supply and demand, with no government intervention, price controls, or monopolistic price setting. Legal and compliance considerations surrounding intellectual property, regulatory data protection, supply chains, and market access remain critical in the global pharma landscape.

National laws and regulations designed to balance important and essential innovation incentives with affordability have strong economic impact and determine patient access to medicines in the U.S., Europe, and beyond. Improving medicine access requires addressing affordability barriers with other systemic factors, such as:

• Debating transparent medicinal product pricing and patient-centred pharmacoeconomic models;
• Examining and addressing the root causes of low or delayed access to biologics and ATMPs;
• Using AI to help design adaptive healthcare and innovation supply chain and procurement systems that focus on enhancing patient access;
• Balancing confidentiality with transparency and accountability in public spending to promote competitive pricing and innovative procurement;
• Working together to achieve transatlantic legal and regulatory stability, including through the European Union’s Life Sciences Strategy, European Innovation Act, Pharmaceutical Package, and Critical Medicines Act.

#USA #EU #healthcare #innovation #marketaccess #pharmaceuticals #biologics #biotech #lifesciences #transatlantic #trade